Citi downgraded telehealth company Hims & Hers Health (NYSE:HIMS) to Sell from Neutral and upgraded value-based care provider agilon health (NYSE:AGL) to Neutral from Sell on Friday as part of its ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...

These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal ...